Mizuho Analysts Give Teva Pharmaceutical Industries (NYSE:TEVA) a $11.00 Price Target

Share on StockTwits

Mizuho set a $11.00 target price on Teva Pharmaceutical Industries (NYSE:TEVA) in a research report report published on Monday morning, Stock Target Advisor reports. The firm currently has a hold rating on the stock.

Several other equities analysts also recently commented on the stock. Citigroup set a $13.00 price target on shares of Teva Pharmaceutical Industries and gave the company a buy rating in a report on Monday. Oppenheimer set a $12.00 price target on shares of Teva Pharmaceutical Industries and gave the company a buy rating in a report on Wednesday, June 12th. Cantor Fitzgerald cut their price target on shares of Teva Pharmaceutical Industries from $16.00 to $9.00 and set a neutral rating on the stock in a report on Wednesday, June 12th. Barclays began coverage on shares of Teva Pharmaceutical Industries in a report on Tuesday, June 11th. They set an underweight rating and a $8.00 price target on the stock. Finally, CIBC upgraded shares of Teva Pharmaceutical Industries from a market perform rating to an outperform rating and set a $12.00 price target on the stock in a report on Monday, June 3rd. Five equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, four have given a buy rating and one has given a strong buy rating to the company. Teva Pharmaceutical Industries has an average rating of Hold and a consensus price target of $16.00.

Teva Pharmaceutical Industries stock opened at $8.18 on Monday. Teva Pharmaceutical Industries has a twelve month low of $7.96 and a twelve month high of $25.96. The company has a debt-to-equity ratio of 1.66, a quick ratio of 0.62 and a current ratio of 0.96. The stock has a market capitalization of $8.34 billion, a PE ratio of 2.92, a price-to-earnings-growth ratio of 0.99 and a beta of 1.64.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Thursday, May 2nd. The company reported $0.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 18.66% and a positive return on equity of 16.84%. The firm had revenue of $4.30 billion for the quarter, compared to the consensus estimate of $4.38 billion. During the same period in the previous year, the firm posted $0.94 EPS. The business’s quarterly revenue was down 15.2% on a year-over-year basis. On average, equities analysts forecast that Teva Pharmaceutical Industries will post 2.26 earnings per share for the current fiscal year.

In other Teva Pharmaceutical Industries news, VP Notaristefani Carlo De sold 16,070 shares of the business’s stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $11.42, for a total value of $183,519.40. Following the completion of the sale, the vice president now directly owns 49,659 shares of the company’s stock, valued at approximately $567,105.78. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Sol J. Barer acquired 111,000 shares of the stock in a transaction on Monday, June 3rd. The stock was bought at an average cost of $8.98 per share, with a total value of $996,780.00. Following the completion of the transaction, the director now owns 115,942 shares in the company, valued at $1,041,159.16. The disclosure for this purchase can be found here. 0.49% of the stock is owned by insiders.

Institutional investors have recently added to or reduced their stakes in the business. Northwestern Mutual Wealth Management Co. lifted its position in shares of Teva Pharmaceutical Industries by 4.0% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 19,861 shares of the company’s stock worth $311,000 after purchasing an additional 767 shares during the period. ARK Investment Management LLC lifted its position in shares of Teva Pharmaceutical Industries by 3.6% in the 1st quarter. ARK Investment Management LLC now owns 24,462 shares of the company’s stock worth $384,000 after purchasing an additional 856 shares during the period. Hancock Whitney Corp lifted its position in shares of Teva Pharmaceutical Industries by 7.8% in the 4th quarter. Hancock Whitney Corp now owns 12,056 shares of the company’s stock worth $186,000 after purchasing an additional 868 shares during the period. Lindbrook Capital LLC lifted its position in shares of Teva Pharmaceutical Industries by 61.2% in the 1st quarter. Lindbrook Capital LLC now owns 2,489 shares of the company’s stock worth $39,000 after purchasing an additional 945 shares during the period. Finally, CIBC Private Wealth Group LLC lifted its position in shares of Teva Pharmaceutical Industries by 1.2% in the 4th quarter. CIBC Private Wealth Group LLC now owns 87,540 shares of the company’s stock worth $1,350,000 after purchasing an additional 1,000 shares during the period. 65.08% of the stock is owned by institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Story: CBOE Russell 2000® Volatility Index

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

William I. Jacobs Sells 600 Shares of Global Payments Inc  Stock
William I. Jacobs Sells 600 Shares of Global Payments Inc Stock
Stewart Butterfield Sells 2,500 Shares of Slack  Stock
Stewart Butterfield Sells 2,500 Shares of Slack Stock
Alice Lindsay Caulder Sells 501 Shares of World Acceptance Corp.  Stock
Alice Lindsay Caulder Sells 501 Shares of World Acceptance Corp. Stock
Insider Buying: ALS Ltd  Insider Buys 14,983 Shares of Stock
Insider Buying: ALS Ltd Insider Buys 14,983 Shares of Stock
Opko Health Inc.  CEO Purchases $106,000.00 in Stock
Opko Health Inc. CEO Purchases $106,000.00 in Stock
Robert Langer Sells 7,500 Shares of Rubius Therapeutics Inc  Stock
Robert Langer Sells 7,500 Shares of Rubius Therapeutics Inc Stock


© 2006-2019 Ticker Report